Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Metabolic Syndrome and Related Disorders|August 24, 2023
Cardiometabolic Risk Increased in Working-Aged Adults During the COVID-19 PandemicMaren S Fragala, Fumika Matsushita, Zhen Chen, et al.
JAMA Network Open|May 19, 2021
Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age AdultsYonghong Li, Carmen H Tong, Lance A Bare, et al.
Scientific Reports|November 29, 2025
Large-scale comparison of two immunoassays for adrenocorticotropic hormone in human plasmaYonghong Li, Judy Z Louie, Thomas E Burgess, et al.
The Journal of Clinical Endocrinology and Metabolism|May 15, 2026
US Patterns in Clinical Islet Autoantibody Ordering and Results Show Key Differences After Teplizumab Regulatory ApprovalSanjay B Dixit, Marco Marcelli, Carmen Tong, et al.
Plos One|June 30, 2025
Real-world Lyme disease testing results using modified vs standard two-tier test protocolsYonghong Li, Zhen Chen, Carmen H Tong, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 6, 2023
Prediction of Future Medical Costs by Modifiable Measures of HealthFarnoosh Haji-Sheikhi, Maren S Fragala, Lance A Bare, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast CancerYonghong Li, Andre R Arellano, Lance A Bare, et al.
BMC Cardiovascular Disorders|October 1, 2015
Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysisDov Shiffman, Marco V Perez, Lance A Bare, et al.
Public Health Reports (Washington, D.C. : 1974)|April 1, 2025
Sex- and Age-Specific Lyme Disease Testing Patterns in the United States, 2019 and 2022Yonghong Li, Fumika Matsushita, Zhen Chen, et al.
BMC Cardiovascular Disorders|December 9, 2016
Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysisDov Shiffman, Andre R Arellano, Michael P Caulfield, et al.
Pageof 4